Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $19.88

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been assigned a consensus recommendation of “Hold” from the twelve analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $19.8750.

A number of brokerages recently commented on JSPR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Thursday, January 22nd. UBS Group assumed coverage on shares of Jasper Therapeutics in a research report on Monday, March 23rd. They set a “neutral” rating for the company. Finally, Rodman & Renshaw initiated coverage on Jasper Therapeutics in a research note on Tuesday, January 13th. They set a “buy” rating and a $17.00 price objective on the stock.

Hedge Funds Weigh In On Jasper Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new position in Jasper Therapeutics in the 1st quarter worth approximately $46,000. Marex Group plc purchased a new stake in shares of Jasper Therapeutics during the second quarter valued at approximately $74,000. Engineers Gate Manager LP bought a new position in shares of Jasper Therapeutics in the second quarter worth approximately $78,000. Panagora Asset Management Inc. bought a new position in shares of Jasper Therapeutics in the fourth quarter worth approximately $35,000. Finally, Voleon Capital Management LP purchased a new position in shares of Jasper Therapeutics in the third quarter worth $50,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Stock Performance

Shares of JSPR opened at $1.05 on Friday. Jasper Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $7.19. The firm has a market cap of $29.38 million, a price-to-earnings ratio of -0.18 and a beta of 3.08. The firm has a 50 day moving average price of $1.34 and a 200-day moving average price of $1.79.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.